Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Sarm1 deletion reduces axon damage, demyelination, and white matter atrophy after experimental traumatic brain injury.

Marion CM, McDaniel DP, Armstrong RC.

Exp Neurol. 2019 Nov;321:113040. doi: 10.1016/j.expneurol.2019.113040. Epub 2019 Aug 21.

2.

Experimental Traumatic Brain Injury Identifies Distinct Early and Late Phase Axonal Conduction Deficits of White Matter Pathophysiology, and Reveals Intervening Recovery.

Marion CM, Radomski KL, Cramer NP, Galdzicki Z, Armstrong RC.

J Neurosci. 2018 Oct 10;38(41):8723-8736. doi: 10.1523/JNEUROSCI.0819-18.2018. Epub 2018 Aug 24.

3.

Genetic detection of Sonic hedgehog (Shh) expression and cellular response in the progression of acute through chronic demyelination and remyelination.

Sanchez MA, Sullivan GM, Armstrong RC.

Neurobiol Dis. 2018 Jul;115:145-156. doi: 10.1016/j.nbd.2018.04.003. Epub 2018 Apr 6.

4.
5.

Postnatal Sonic hedgehog (Shh) responsive cells give rise to oligodendrocyte lineage cells during myelination and in adulthood contribute to remyelination.

Sanchez MA, Armstrong RC.

Exp Neurol. 2018 Jan;299(Pt A):122-136. doi: 10.1016/j.expneurol.2017.10.010. Epub 2017 Oct 16.

6.

The Biological Basis of Chronic Traumatic Encephalopathy following Blast Injury: A Literature Review.

Aldag M, Armstrong RC, Bandak F, Bellgowan PSF, Bentley T, Biggerstaff S, Caravelli K, Cmarik J, Crowder A, DeGraba TJ, Dittmer TA, Ellenbogen RG, Greene C, Gupta RK, Hicks R, Hoffman S, Latta RC 3rd, Leggieri MJ Jr, Marion D, Mazzoli R, McCrea M, O'Donnell J, Packer M, Petro JB, Rasmussen TE, Sammons-Jackson W, Shoge R, Tepe V, Tremaine LA, Zheng J.

J Neurotrauma. 2017 Sep;34(S1):S26-S43. doi: 10.1089/neu.2017.5218. Review.

7.

Leukemia/lymphoma-related factor (LRF) exhibits stage- and context-dependent transcriptional controls in the oligodendrocyte lineage and modulates remyelination.

Davidson NL, Yu F, Kijpaisalratana N, Le TQ, Beer LA, Radomski KL, Armstrong RC.

J Neurosci Res. 2017 Dec;95(12):2391-2408. doi: 10.1002/jnr.24083. Epub 2017 May 30.

8.

Microstructural Rearrangements and their Rheological Implications in a Model Thixotropic Elastoviscoplastic Fluid.

Jamali S, McKinley GH, Armstrong RC.

Phys Rev Lett. 2017 Jan 27;118(4):048003. doi: 10.1103/PhysRevLett.118.048003. Epub 2017 Jan 27.

PMID:
28186811
9.

Myelin and oligodendrocyte lineage cells in white matter pathology and plasticity after traumatic brain injury.

Armstrong RC, Mierzwa AJ, Sullivan GM, Sanchez MA.

Neuropharmacology. 2016 Nov;110(Pt B):654-659. doi: 10.1016/j.neuropharm.2015.04.029. Epub 2015 May 9. Review.

10.

Repetitive Model of Mild Traumatic Brain Injury Produces Cortical Abnormalities Detectable by Magnetic Resonance Diffusion Imaging, Histopathology, and Behavior.

Yu F, Shukla DK, Armstrong RC, Marion CM, Radomski KL, Selwyn RG, Dardzinski BJ.

J Neurotrauma. 2017 Apr 1;34(7):1364-1381. doi: 10.1089/neu.2016.4569. Epub 2016 Dec 20.

11.

Publisher's Note: Characterizing short-term stability for Boolean networks over any distribution of transfer functions [Phys. Rev. E 94, 012301 (2016)].

Seshadhri C, Smith AM, Vorobeychik Y, Mayo JR, Armstrong RC.

Phys Rev E. 2016 Sep;94(3-2):039901. Epub 2016 Sep 14.

PMID:
27739754
12.

Characterizing short-term stability for Boolean networks over any distribution of transfer functions.

Seshadhri C, Smith AM, Vorobeychik Y, Mayo JR, Armstrong RC.

Phys Rev E. 2016 Jul;94(1-1):012301. doi: 10.1103/PhysRevE.94.012301. Epub 2016 Jul 5. Erratum in: Phys Rev E. 2016 Sep;94(3-2):039901.

PMID:
27575142
13.

Characterisation of interface astroglial scarring in the human brain after blast exposure: a post-mortem case series.

Shively SB, Horkayne-Szakaly I, Jones RV, Kelly JP, Armstrong RC, Perl DP.

Lancet Neurol. 2016 Aug;15(9):944-953. doi: 10.1016/S1474-4422(16)30057-6. Epub 2016 Jun 9.

PMID:
27291520
14.

Variations in Patterns of Utilization and Charges for the Care of Low Back Pain in North Carolina, 2000 to 2009: A Statewide Claims' Data Analysis.

Hurwitz EL, Li D, Guillen J, Schneider MJ, Stevans JM, Phillips RB, Phelan SP, Lewis EA, Armstrong RC, Vassilaki M.

J Manipulative Physiol Ther. 2016 May;39(4):252-62. doi: 10.1016/j.jmpt.2016.02.006.

PMID:
27166406
15.

Variations in Patterns of Utilization and Charges for the Care of Neck Pain in North Carolina, 2000 to 2009: A Statewide Claims' Data Analysis.

Hurwitz EL, Li D, Guillen J, Schneider MJ, Stevans JM, Phillips RB, Phelan SP, Lewis EA, Armstrong RC, Vassilaki M.

J Manipulative Physiol Ther. 2016 May;39(4):240-51. doi: 10.1016/j.jmpt.2016.02.007.

PMID:
27166405
16.

Variations in Patterns of Utilization and Charges for the Care of Headache in North Carolina, 2000-2009: A Statewide Claims' Data Analysis.

Hurwitz EL, Vassilaki M, Li D, Schneider MJ, Stevans JM, Phillips RB, Phelan SP, Lewis EA, Armstrong RC.

J Manipulative Physiol Ther. 2016 May;39(4):229-39. doi: 10.1016/j.jmpt.2016.02.008.

PMID:
27166404
17.

Outcome after Repetitive Mild Traumatic Brain Injury Is Temporally Related to Glucose Uptake Profile at Time of Second Injury.

Selwyn RG, Cooney SJ, Khayrullina G, Hockenbury N, Wilson CM, Jaiswal S, Bermudez S, Armstrong RC, Byrnes KR.

J Neurotrauma. 2016 Aug 15;33(16):1479-91. doi: 10.1089/neu.2015.4129. Epub 2016 Feb 11.

PMID:
26650903
18.

Discovery and optimization of a highly efficacious class of 5-aryl-2-aminopyridines as FMS-like tyrosine kinase 3 (FLT3) inhibitors.

Liu G, Abraham S, Liu X, Xu S, Rooks AM, Nepomuceno R, Dao A, Brigham D, Gitnick D, Insko DE, Gardner MF, Zarrinkar PP, Christopher R, Belli B, Armstrong RC, Holladay MW.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3436-41. doi: 10.1016/j.bmcl.2015.07.023. Epub 2015 Jul 14.

PMID:
26208887
19.

White matter involvement after TBI: Clues to axon and myelin repair capacity.

Armstrong RC, Mierzwa AJ, Marion CM, Sullivan GM.

Exp Neurol. 2016 Jan;275 Pt 3:328-333. doi: 10.1016/j.expneurol.2015.02.011. Epub 2015 Feb 16. Review.

20.

Components of myelin damage and repair in the progression of white matter pathology after mild traumatic brain injury.

Mierzwa AJ, Marion CM, Sullivan GM, McDaniel DP, Armstrong RC.

J Neuropathol Exp Neurol. 2015 Mar;74(3):218-32. doi: 10.1097/NEN.0000000000000165.

21.

Characterization and assessment of hyperelastic and elastic properties of decellularized human adipose tissues.

Omidi E, Fuetterer L, Reza Mousavi S, Armstrong RC, Flynn LE, Samani A.

J Biomech. 2014 Nov 28;47(15):3657-63. doi: 10.1016/j.jbiomech.2014.09.035. Epub 2014 Oct 7.

PMID:
25446266
22.
23.

Oligodendrocyte lineage and subventricular zone response to traumatic axonal injury in the corpus callosum.

Sullivan GM, Mierzwa AJ, Kijpaisalratana N, Tang H, Wang Y, Song SK, Selwyn R, Armstrong RC.

J Neuropathol Exp Neurol. 2013 Dec;72(12):1106-25. doi: 10.1097/NEN.0000000000000009.

24.

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M.

J Clin Oncol. 2013 Oct 10;31(29):3681-7. doi: 10.1200/JCO.2013.48.8783. Epub 2013 Sep 3.

25.

Mild traumatic brain injury results in depressed cerebral glucose uptake: An (18)FDG PET study.

Selwyn R, Hockenbury N, Jaiswal S, Mathur S, Armstrong RC, Byrnes KR.

J Neurotrauma. 2013 Dec 1;30(23):1943-53. doi: 10.1089/neu.2013.2928. Epub 2013 Oct 2.

PMID:
23829400
26.

FGF2 and FGFR1 signaling regulate functional recovery following cuprizone demyelination.

Mierzwa AJ, Zhou YX, Hibbits N, Vana AC, Armstrong RC.

Neurosci Lett. 2013 Aug 26;548:280-5. doi: 10.1016/j.neulet.2013.05.010. Epub 2013 May 14.

27.

Transient exposure to quizartinib mediates sustained inhibition of FLT3 signaling while specifically inducing apoptosis in FLT3-activated leukemia cells.

Gunawardane RN, Nepomuceno RR, Rooks AM, Hunt JP, Ricono JM, Belli B, Armstrong RC.

Mol Cancer Ther. 2013 Apr;12(4):438-47. doi: 10.1158/1535-7163.MCT-12-0305. Epub 2013 Feb 14.

28.

Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases.

Liu G, Campbell BT, Holladay MW, Ford Pulido JM, Hua H, Gitnick D, Gardner MF, James J, Breider MA, Brigham D, Belli B, Armstrong RC, Treiber DK.

ACS Med Chem Lett. 2012 Sep 24;3(12):997-1002. doi: 10.1021/ml300214g. eCollection 2012 Dec 13.

29.

Astrogliosis during acute and chronic cuprizone demyelination and implications for remyelination.

Hibbits N, Yoshino J, Le TQ, Armstrong RC.

ASN Neuro. 2012 Oct 30;4(6):393-408. doi: 10.1042/AN20120062.

30.

Leukemia/lymphoma-related factor regulates oligodendrocyte lineage cell differentiation in developing white matter.

Dobson NR, Moore RT, Tobin JE, Armstrong RC.

Glia. 2012 Sep;60(9):1378-90. doi: 10.1002/glia.22356. Epub 2012 May 21.

PMID:
22615173
31.

Discovery of highly potent and selective pan-Aurora kinase inhibitors with enhanced in vivo antitumor therapeutic index.

Liu G, Abraham S, Tran L, Vickers TD, Xu S, Hadd MJ, Quiambao S, Holladay MW, Hua H, Ford Pulido JM, Gunawardane RN, Davis MI, Eichelberger SR, Apuy JL, Gitnick D, Gardner MF, James J, Breider MA, Belli B, Armstrong RC, Treiber DK.

J Med Chem. 2012 Apr 12;55(7):3250-60. doi: 10.1021/jm201702g. Epub 2012 Mar 14.

PMID:
22380736
32.

CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.

James J, Ruggeri B, Armstrong RC, Rowbottom MW, Jones-Bolin S, Gunawardane RN, Dobrzanski P, Gardner MF, Zhao H, Cramer MD, Hunter K, Nepomuceno RR, Cheng M, Gitnick D, Yazdanian M, Insko DE, Ator MA, Apuy JL, Faraoni R, Dorsey BD, Williams M, Bhagwat SS, Holladay MW.

Mol Cancer Ther. 2012 Apr;11(4):930-41. doi: 10.1158/1535-7163.MCT-11-0645. Epub 2012 Feb 7.

33.

Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.

Rowbottom MW, Faraoni R, Chao Q, Campbell BT, Lai AG, Setti E, Ezawa M, Sprankle KG, Abraham S, Tran L, Struss B, Gibney M, Armstrong RC, Gunawardane RN, Nepomuceno RR, Valenta I, Hua H, Gardner MF, Cramer MD, Gitnick D, Insko DE, Apuy JL, Jones-Bolin S, Ghose AK, Herbertz T, Ator MA, Dorsey BD, Ruggeri B, Williams M, Bhagwat S, James J, Holladay MW.

J Med Chem. 2012 Feb 9;55(3):1082-105. doi: 10.1021/jm2009925. Epub 2012 Jan 23.

PMID:
22168626
34.

Noncooperatively optimized tolerance: decentralized strategic optimization in complex systems.

Vorobeychik Y, Mayo JR, Armstrong RC, Ruthruff JR.

Phys Rev Lett. 2011 Sep 2;107(10):108702. Epub 2011 Sep 1.

PMID:
21981540
35.

Influence and dynamic behavior in random boolean networks.

Seshadhri C, Vorobeychik Y, Mayo JR, Armstrong RC, Ruthruff JR.

Phys Rev Lett. 2011 Sep 2;107(10):108701. Epub 2011 Sep 1.

PMID:
21981539
36.

Fibroblast growth factor 1 (FGFR1) modulation regulates repair capacity of oligodendrocyte progenitor cells following chronic demyelination.

Zhou YX, Pannu R, Le TQ, Armstrong RC.

Neurobiol Dis. 2012 Jan;45(1):196-205. doi: 10.1016/j.nbd.2011.08.004. Epub 2011 Aug 10.

37.

4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors.

Holladay MW, Campbell BT, Rowbottom MW, Chao Q, Sprankle KG, Lai AG, Abraham S, Setti E, Faraoni R, Tran L, Armstrong RC, Gunawardane RN, Gardner MF, Cramer MD, Gitnick D, Ator MA, Dorsey BD, Ruggeri BR, Williams M, Bhagwat SS, James J.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5342-6. doi: 10.1016/j.bmcl.2011.07.019. Epub 2011 Jul 14.

PMID:
21807507
38.

Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.

Abraham S, Hadd MJ, Tran L, Vickers T, Sindac J, Milanov ZV, Holladay MW, Bhagwat SS, Hua H, Ford Pulido JM, Cramer MD, Gitnick D, James J, Dao A, Belli B, Armstrong RC, Treiber DK, Liu G.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5296-300. doi: 10.1016/j.bmcl.2011.07.027. Epub 2011 Jul 14.

PMID:
21802948
39.

Reduced axonopathy and enhanced remyelination after chronic demyelination in fibroblast growth factor 2 (Fgf2)-null mice: differential detection with diffusion tensor imaging.

Tobin JE, Xie M, Le TQ, Song SK, Armstrong RC.

J Neuropathol Exp Neurol. 2011 Feb;70(2):157-65. doi: 10.1097/NEN.0b013e31820937e4.

40.

Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP, Treiber DK.

Chem Biol. 2010 Nov 24;17(11):1241-9. doi: 10.1016/j.chembiol.2010.09.010.

41.

Rostrocaudal analysis of corpus callosum demyelination and axon damage across disease stages refines diffusion tensor imaging correlations with pathological features.

Xie M, Tobin JE, Budde MD, Chen CI, Trinkaus K, Cross AH, McDaniel DP, Song SK, Armstrong RC.

J Neuropathol Exp Neurol. 2010 Jul;69(7):704-16. doi: 10.1097/NEN.0b013e3181e3de90.

42.

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).

Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q, Sprankle KG, Patel HK, Levis M, Armstrong RC, James J, Bhagwat SS.

Blood. 2009 Oct 1;114(14):2984-92. doi: 10.1182/blood-2009-05-222034. Epub 2009 Aug 4.

43.

Cuprizone demyelination of the corpus callosum in mice correlates with altered social interaction and impaired bilateral sensorimotor coordination.

Hibbits N, Pannu R, Wu TJ, Armstrong RC.

ASN Neuro. 2009 Aug 14;1(3). pii: e00013. doi: 10.1042/AN20090032.

45.

Initiation of oligodendrocyte progenitor cell migration by a PDGF-A activated extracellular regulated kinase (ERK) signaling pathway.

Frost EE, Zhou Z, Krasnesky K, Armstrong RC.

Neurochem Res. 2009 Jan;34(1):169-81. doi: 10.1007/s11064-008-9748-z. Epub 2008 May 30.

46.

Myelin repair strategies: a cellular view.

Gallo V, Armstrong RC.

Curr Opin Neurol. 2008 Jun;21(3):278-83. doi: 10.1097/WCO.0b013e3282fd1875. Review.

47.

Musashi1 RNA-binding protein regulates oligodendrocyte lineage cell differentiation and survival.

Dobson NR, Zhou YX, Flint NC, Armstrong RC.

Glia. 2008 Feb;56(3):318-30.

48.

Platelet-derived growth factor promotes repair of chronically demyelinated white matter.

Vana AC, Flint NC, Harwood NE, Le TQ, Fruttiger M, Armstrong RC.

J Neuropathol Exp Neurol. 2007 Nov;66(11):975-88.

49.
50.

Myelin transcription factor 1 (Myt1) expression in demyelinated lesions of rodent and human CNS.

Vana AC, Lucchinetti CF, Le TQ, Armstrong RC.

Glia. 2007 May;55(7):687-97.

Supplemental Content

Loading ...
Support Center